Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Deferred Taxes (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Deferred Taxes for 12 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 113.44% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.2 million through Dec 2025, up 164.97% year-over-year, with the annual reading at $14.2 million for FY2025, 164.97% up from the prior year.
  • Deferred Taxes hit $2.4 million in Q4 2025 for Ani Pharmaceuticals, down from $18.8 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $18.8 million in Q3 2025 to a low of -$17.5 million in Q4 2024.
  • Historically, Deferred Taxes has averaged -$2.6 million across 5 years, with a median of -$2.8 million in 2022.
  • Biggest five-year swings in Deferred Taxes: plummeted 2575.27% in 2022 and later surged 436.44% in 2025.
  • Year by year, Deferred Taxes stood at -$8.1 million in 2021, then surged by 79.91% to -$1.6 million in 2022, then plummeted by 413.6% to -$8.3 million in 2023, then tumbled by 110.04% to -$17.5 million in 2024, then surged by 113.44% to $2.4 million in 2025.
  • Business Quant data shows Deferred Taxes for ANIP at $2.4 million in Q4 2025, $18.8 million in Q3 2025, and -$3.5 million in Q2 2025.